Integra LifeSciences price target lowered to $13 from $15 at Wells Fargo
Wells Fargo reduced its price target for Integra LifeSciences (IART) from $15 to $13, maintaining an Equal Weight rating. The firm cited Q3 results meeting guidance but emphasized concerns about recovery pace and offsetting factors like Neuro strength and product relaunch.
How this was made
The 30-second read
Why it matters
The downgrade highlights concerns about recovery speed and financing costs, which could depress the stock.
Market read
Analyst target reduction is a fresh catalyst that may trigger short‑term selling pressure.
What to watch
Potential upside from upcoming product relaunches and neuro‑device pipeline not fully reflected in the downgrade.
Background
Integra LifeSciences reported Q3 results in line with guidance despite operational headwinds.
Ticker impact
Wells Fargo cut Integra LifeSciences' price target to $13 from $15, marking a new downgrade.
downward pressure as investors price in the reduced target
Target cut reflects concerns over recovery pace and higher interest expense, likely prompting sell‑side activity.
Market effects
May weigh on the broader medical device sector as analysts reassess recovery timelines.
Limited to U.S. markets where IART trades.
Minimal global impact beyond sector peers.
Counterpoint
Some investors may view the target cut as an overreaction if the company can sustain its Q3 guidance.
Key entities
- AnalystWells Fargo
Equity research firm issuing the new price target.
